Skip to content

Study · Randomized controlled trial · n = 200 · 2026

11 results

[Comparative study of the efficacy and safety of Ranquilon and Afobazol in the treatment of patients with anxiety associated with neurasthenia and adjustment disorders. (Results of an open, randomized, multicenter, phase IV clinical study)].

Karavayeva TA, Barinov AN, Egorov IV, Ebzeeva EY, Ishchenko KA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2026

PMID42565399 (opens in a new tab)DOI10.17116/jnevro202612607151 (opens in a new tab)PepBankPUB-42565399
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with anxiety, all secondary efficacy criteria favored Ranquilon over Afobazol.

    In plain wordsIn patients with anxiety, all secondary efficacy criteria favored Ranquilon over Afobazol.

    Peptide
    GB-115
    Outcome
    IncreaseSecondary efficacy criteria
    Study

    n = 200

    Comparator
    Afobazol
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    All secondary efficacy criteria further demonstrated statistically significant advantages for Group 1 compared to Group 2 (p<0.05).
    3 context sentences
    Summary · context
    The assessment of therapeutic response used the HARS, the Psychological Stress Measure (PSM-25) to evaluate stress levels, the MFI-20 scale to assess asthenia, and the CGI-S subscale to assess the severity of the condition.
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with anxiety associated with neurasthenia or adjustment disorders, HARS response was higher with Ranquilon than Afobazol.

    In plain wordsIn patients with anxiety, Ranquilon produced more HARS responders than Afobazol.

    Peptide
    GB-115
    Outcome
    IncreaseHARS responders
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Measurements

    HARS responders
    63.3%
    Ranquilon
    HARS responders
    49%
    Afobazol
    HARS responders
    62 participants
    Ranquilon
    HARS responders
    49 participants
    Afobazol

    Source sentences

    Summary
    The proportion of responders with a 50% or greater reduction in mean HARS scores at Visit 3 (Day 29±1) compared to baseline (Visit 0) was statistically higher (pn=62) vs. Group 2 (49.0%, n=49).
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with anxiety, adverse events affected 16.0% with Ranquilon and 12.0% with Afobazol, without a significant difference.

    In plain wordsIn patients with anxiety, adverse event frequency did not differ significantly between Ranquilon and Afobazol.

    Peptide
    GB-115
    Outcome
    No significant changeAdverse events
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Measurements

    Adverse events
    16 events
    Ranquilon
    Patients with adverse events
    16%
    Ranquilon
    Patients with adverse events
    16 participants
    Ranquilon
    Adverse events
    13 events
    Afobazol
    Patients with adverse events
    12%
    Afobazol
    Patients with adverse events
    12 participants
    Afobazol

    Source sentences

    Summary
    In total, 29 AEs were reported in 14.0% (n=44) of patients, including 16 AEs in 16.0% (n=16) of patients from Group 1 and 13 AEs in 12.0% (n=12) of patients from Group 2.
    Summary
    There was no significant difference between the treatment groups in the number of patients with AEs (p=0.4150).
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with anxiety, both Ranquilon and Afobazol groups reported only mild adverse events.

    In plain wordsIn patients with anxiety, both Ranquilon and Afobazol groups reported only mild adverse events.

    Peptide
    GB-115
    Outcome
    Not applicableAdverse event severity
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with anxiety, neither Ranquilon nor Afobazol groups reported serious adverse events.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol groups reported serious adverse events.

    Peptide
    GB-115
    Outcome
    Not applicableSerious adverse events
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with anxiety, neither Ranquilon nor Afobazol groups reported severe adverse events.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol groups reported severe adverse events.

    Peptide
    GB-115
    Outcome
    Not applicableSevere adverse events
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with anxiety, neither Ranquilon nor Afobazol groups reported fatal adverse events.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol groups reported fatal adverse events.

    Peptide
    GB-115
    Outcome
    Not applicableFatal adverse events
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Mortality · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with anxiety, neither Ranquilon nor Afobazol groups had adverse events that caused treatment discontinuation.

    In plain wordsIn patients with anxiety, adverse events caused no treatment discontinuations in either Ranquilon or Afobazol groups.

    Peptide
    GB-115
    Outcome
    Not applicableAdverse event discontinuations
    Study

    n = 200

    Comparator
    Afobazol
    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  9. 09HumanRandomized controlled trialSafety outcome

    In patients with anxiety, no clinically significant vital sign abnormalities were observed during Ranquilon or Afobazol treatment.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol treatment showed clinically significant vital sign abnormalities.

    Peptide
    GB-115
    Outcome
    Not applicableVital sign abnormalities
    Study

    n = 200

    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    No clinically significant abnormalities were observed in vital signs, laboratory tests, or ECG assessments.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  10. 10HumanRandomized controlled trialSafety outcome

    In patients with anxiety, no clinically significant laboratory abnormalities were observed during Ranquilon or Afobazol treatment.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol treatment showed clinically significant laboratory abnormalities.

    Peptide
    GB-115
    Outcome
    Not applicableLaboratory abnormalities
    Study

    n = 200

    Outcome group
    Adverse events · Whole body
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    No clinically significant abnormalities were observed in vital signs, laboratory tests, or ECG assessments.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days
  11. 11HumanRandomized controlled trialSafety outcome

    In patients with anxiety, no clinically significant ECG abnormalities were observed during Ranquilon or Afobazol treatment.

    In plain wordsIn patients with anxiety, neither Ranquilon nor Afobazol treatment showed clinically significant ECG abnormalities.

    Peptide
    GB-115
    Outcome
    Not applicableECG abnormalities
    Study

    n = 200

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    6 mg/day · oral · 28 daysAs given in this study (human).

    Source sentences

    Summary
    No clinically significant abnormalities were observed in vital signs, laboratory tests, or ECG assessments.
    2 context sentences
    Summary · context
    The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2).
    Summary · context
    Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg/day (2 tablets three times daily) for 28 days

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.